1: Spahn V, Stein C. Targeting delta opioid receptors for pain treatment: drugs in phase I and II clinical development. Expert Opin Investig Drugs. 2017 Feb;26(2):155-160. doi: 10.1080/13543784.2017.1275562. Epub 2017 Jan 2. Review. PubMed PMID: 28001096.
2: Huang P, Tunis J, Parry C, Tallarida R, Liu-Chen LY. Synergistic antidepressant-like effects between a kappa opioid antagonist (LY2444296) and a delta opioid agonist (ADL5859) in the mouse forced swim test. Eur J Pharmacol. 2016 Jun 15;781:53-9. doi: 10.1016/j.ejphar.2016.03.061. Epub 2016 Apr 1. PubMed PMID: 27044434; PubMed Central PMCID: PMC5444937.
3: Chung PC, Boehrer A, Stephan A, Matifas A, Scherrer G, Darcq E, Befort K, Kieffer BL. Delta opioid receptors expressed in forebrain GABAergic neurons are responsible for SNC80-induced seizures. Behav Brain Res. 2015 Feb 1;278:429-34. doi: 10.1016/j.bbr.2014.10.029. Epub 2014 Oct 30. PubMed PMID: 25447299; PubMed Central PMCID: PMC4382405.
4: Nozaki C, Le Bourdonnec B, Reiss D, Windh RT, Little PJ, Dolle RE, Kieffer BL, Gavériaux-Ruff C. δ-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization. J Pharmacol Exp Ther. 2012 Sep;342(3):799-807. doi: 10.1124/jpet.111.188987. Epub 2012 Jun 13. PubMed PMID: 22700431; PubMed Central PMCID: PMC3422521.
5: Le Bourdonnec B, Windh RT, Ajello CW, Leister LK, Gu M, Chu GH, Tuthill PA, Barker WM, Koblish M, Wiant DD, Graczyk TM, Belanger S, Cassel JA, Feschenko MS, Brogdon BL, Smith SA, Christ DD, Derelanko MJ, Kutz S, Little PJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE. Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859). J Med Chem. 2008 Oct 9;51(19):5893-6. doi: 10.1021/jm8008986. Epub 2008 Sep 13. PubMed PMID: 18788723.